Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Marianne Labussiere

Showing results (1-10 of 7) with videos related to

Pageof 1
Sort By:
The Oncologist|February 6, 2010
IDH1 gene mutations: a new paradigm in glioma prognosis and therapy?Marianne Labussiere, Marc Sanson, Ahmed Idbaih, et al.
Oncology Reports|October 25, 2008
Proteasome inhibition by bortezomib does not translate into efficacy on two malignant glioma xenograftsMarianne Labussiere, Sophie Pinel, Suzanne Delfortrie, et al.
Future Oncology (London, England)|May 15, 2010
Prognostic markers in gliomasMarianne Labussiere, Xiao-Wei Wang, Ahmed Idbaih, et al.
Expert Review of Anticancer Therapy|May 11, 2011
Predictive and prognostic factors for gliomasFrançois Ducray, Ahmed Idbaih, Xiao-Wei Wang, et al.
Journal of Neuro-Oncology|March 22, 2015
Preclinical impact of bevacizumab on brain and tumor distribution of irinotecan and temozolomideLauriane Goldwirt, Kevin Beccaria, Alexandre Carpentier, et al.
Journal of Neuro-Oncology|December 10, 2014
VEGFA SNP rs2010963 is associated with vascular toxicity in recurrent glioblastomas and longer response to bevacizumabAnna Luisa Di Stefano, Marianne Labussiere, Giuseppe Lombardi, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|January 23, 2015
Detection, Characterization, and Inhibition of FGFR-TACC Fusions in IDH Wild-type GliomaAnna Luisa Di Stefano, Alessandra Fucci, Veronique Frattini, et al.
Pageof 1

Showing results (1-10 of 7) with videos related to

Sort By:
Pageof 1
The Oncologist|February 6, 2010
IDH1 gene mutations: a new paradigm in glioma prognosis and therapy?Marianne Labussiere, Marc Sanson, Ahmed Idbaih, et al.
Oncology Reports|October 25, 2008
Proteasome inhibition by bortezomib does not translate into efficacy on two malignant glioma xenograftsMarianne Labussiere, Sophie Pinel, Suzanne Delfortrie, et al.
Future Oncology (London, England)|May 15, 2010
Prognostic markers in gliomasMarianne Labussiere, Xiao-Wei Wang, Ahmed Idbaih, et al.
Expert Review of Anticancer Therapy|May 11, 2011
Predictive and prognostic factors for gliomasFrançois Ducray, Ahmed Idbaih, Xiao-Wei Wang, et al.
Journal of Neuro-Oncology|March 22, 2015
Preclinical impact of bevacizumab on brain and tumor distribution of irinotecan and temozolomideLauriane Goldwirt, Kevin Beccaria, Alexandre Carpentier, et al.
Journal of Neuro-Oncology|December 10, 2014
VEGFA SNP rs2010963 is associated with vascular toxicity in recurrent glioblastomas and longer response to bevacizumabAnna Luisa Di Stefano, Marianne Labussiere, Giuseppe Lombardi, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|January 23, 2015
Detection, Characterization, and Inhibition of FGFR-TACC Fusions in IDH Wild-type GliomaAnna Luisa Di Stefano, Alessandra Fucci, Veronique Frattini, et al.
Pageof 1